Is Mazdutide FDA approved?
No. This profile records Mazdutide as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
Metabolic CATEGORY
Mazdutide
THE DUAL ACTIVATOR
OXM3; IBI362; LY3305677
Mazdutide is a dual GLP-1/glucagon receptor agonist being developed for obesity and type 2 diabetes. Unlike single-target drugs like semaglutide, it activates both receptors for potentially greater weight loss. The GLP-1 action reduces appetite and slows digestion, while glucagon activation increases energy expenditure and fat burning.
Mazdutide
Mazdutide
Mazdutide
Mazdutide Evidence Snapshot
How these guides are reviewed
REGULATORY STATUS
Not FDA approved · research use only
DOSING GUIDANCE
Reviewed by our clinical team
LINKED EVIDENCE
1 research sources
CONTENT UPDATED
Sep 1, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
Quick Answers About Mazdutide
What dose does The Peptide App Clinical Team recommend for Mazdutide?
Dose: 1-6 mg once weekly (subcutaneous injection).
MORE CONTEXT ›
Schedule: weekly. Cycle: Ongoing as prescribed in clinical trials. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
What research supports this Mazdutide guide?
This guide links to 1 curated or current research sources.
MORE CONTEXT ›
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Studied Effects & Mechanisms
Appetite Suppression
GLP-1 activation reduces hunger and food intake
Increased Thermogenesis
Glucagon receptor activation boosts energy expenditure
Glucose Control
Improves insulin secretion and blood sugar regulation
Gastric Slowing
Delays stomach emptying for prolonged satiety
Those with significant weight to lose
People with type 2 diabetes
Those who haven't responded well to GLP-1 alone
Those interested in cutting-edge obesity treatments
Mazdutide Research
Live research temporarily unavailableThe live research feed did not return papers for this page. The curated references below remain available for crawlable source context.
RESEARCH REFERENCES